Cookson Peirce & Co. Inc. Purchases Shares of 40,449 Adaptive Biotechnologies Corporation $ADPT

Cookson Peirce & Co. Inc. acquired a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,449 shares of the company’s stock, valued at approximately $868,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ADPT. California State Teachers Retirement System grew its holdings in shares of Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after purchasing an additional 933 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after buying an additional 941 shares in the last quarter. Captrust Financial Advisors boosted its position in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares in the last quarter. Assetmark Inc. grew its stake in Adaptive Biotechnologies by 46.4% during the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after buying an additional 1,401 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 321,324 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.08, for a total value of $8,058,805.92. Following the transaction, the chief executive officer owned 2,180,518 shares in the company, valued at $54,687,391.44. This trade represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Harlan S. Robins sold 492,400 shares of Adaptive Biotechnologies stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the sale, the insider owned 812,058 shares of the company’s stock, valued at approximately $17,775,949.62. The trade was a 37.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,062,325 shares of company stock valued at $46,659,069 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ADPT shares. Morgan Stanley lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Piper Sandler raised their price target on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. TD Cowen lifted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, Guggenheim increased their target price on Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.42.

Adaptive Biotechnologies Price Performance

ADPT opened at $25.19 on Monday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. The stock has a market capitalization of $4.02 billion, a P/E ratio of -61.44 and a beta of 2.08. The company’s 50 day simple moving average is $22.92 and its 200-day simple moving average is $17.66. Adaptive Biotechnologies Corporation has a one year low of $12.00 and a one year high of $26.87.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The firm had revenue of $71.55 million for the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) EPS. Sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.